There are 33 resources available
33O - PRIMA/ENGOT-OV26/GOG-3012 study: long-term conditional PFS
Presenter: Antonio Jose Gonzalez Martin
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 32O and 33O
Presenter: Kathleen Moore
Session: Proffered Paper session
Resources:
Slides
Webcast
Invited Discussant of abstract 34O
Presenter: Jean Emmanuel Kurtz
Session: Proffered Paper session
Resources:
Slides
Webcast
35O - Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Adjusted for Subsequent PARPi Use in Placebo Group: Results from an Ad Hoc Interim Analysis for the Phase 3 NORA Study
Presenter: Xiaohua Wu
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstract 35O
Presenter: Jonathan Ledermann
Session: Proffered Paper session
Resources:
Slides
Webcast
Why are we having this Symposium? Recent regulatory actions by FDA/EMEA regarding late-stage approval for PARPi in recurrent ovarian cancer
Presenter: Robert Coleman
Session: How to interpret overall survival data with PARP inhibitors
Resources:
Slides
Webcast
Is there clinical evidence to support the link between PARPi use and a negative impact on OS?
Presenter: Jonathan Ledermann
Session: How to interpret overall survival data with PARP inhibitors
Resources:
Slides
Webcast
Is there a biological rationale to support decremental impact on overall survival?
Presenter: Antonio Jose Gonzalez Martin
Session: How to interpret overall survival data with PARP inhibitors
Resources:
Slides
Webcast
Welcome to the ESMO Gynaecological Cancers Congress 2023
Presenter: The Chairs
Session: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023
Resources:
Slides
Webcast
Introduction
Presenter: Susana Banerjee
Session: Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023
Resources:
Webcast